Ocular Therapeutix (OCUL) vs. Steris Plc (STE) Financial Survey
Ocular Therapeutix (NASDAQ: OCUL) and Steris Plc (NYSE:STE) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, valuation, institutional ownership, profitability and analyst recommendations.
This table compares Ocular Therapeutix and Steris Plc’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Steris Plc pays an annual dividend of $1.24 per share and has a dividend yield of 1.4%. Ocular Therapeutix does not pay a dividend. Steris Plc pays out 88.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Steris Plc has raised its dividend for 7 consecutive years.
Volatility and Risk
Ocular Therapeutix has a beta of 1.6, meaning that its stock price is 60% more volatile than the S&P 500. Comparatively, Steris Plc has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500.
Valuation and Earnings
This table compares Ocular Therapeutix and Steris Plc’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Ocular Therapeutix||$1.90 million||98.18||-$54.64 million||($2.13)||-3.01|
|Steris Plc||$2.58 billion||2.87||$521.33 million||$1.40||62.00|
Steris Plc has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Steris Plc, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
53.4% of Ocular Therapeutix shares are held by institutional investors. Comparatively, 94.7% of Steris Plc shares are held by institutional investors. 26.1% of Ocular Therapeutix shares are held by insiders. Comparatively, 2.6% of Steris Plc shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This is a summary of current ratings and target prices for Ocular Therapeutix and Steris Plc, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Ocular Therapeutix currently has a consensus price target of $24.00, suggesting a potential upside of 273.83%. Steris Plc has a consensus price target of $85.00, suggesting a potential downside of 2.07%. Given Ocular Therapeutix’s stronger consensus rating and higher probable upside, equities analysts plainly believe Ocular Therapeutix is more favorable than Steris Plc.
Steris Plc beats Ocular Therapeutix on 9 of the 16 factors compared between the two stocks.
Ocular Therapeutix Company Profile
Ocular Therapeutix, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye. Its lead product candidates are DEXTENZA (dexamethasone insert), for the treatment of post-surgical ocular inflammation and pain, allergic conjunctivitis and dry eye disease, and OTX-TP, for the treatment of glaucoma and ocular hypertension, which are extended-delivery, drug-eluting inserts that are placed into the canaliculus through a natural opening called the punctum located in the inner portion of the eyelid near the nose. It also has an intravitreal hydrogel depot, which is in preclinical development for the treatment of diseases and conditions of the back of the eye, including wet age-related macular degeneration (wet AMD).
Steris Plc Company Profile
STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others. Its Corporate and other segment includes the Defense and Industrial business unit.
Receive News & Ratings for Ocular Therapeutix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.